1
|
Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, Gottstein J, Walter L, Braicu EI, Sehouli J, Darb-Esfahani S, Staebler A, Hartkopf AD, Brucker S, Wallwiener D, Beyer I, Niederacher D, Fehm T, Templin MF, Neubauer H. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Mol Cancer Res 2019; 18:278-286. [DOI: 10.1158/1541-7786.mcr-19-0141] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 06/28/2019] [Accepted: 11/04/2019] [Indexed: 12/24/2022]
|
2
|
Kersting D, Fasbender S, Pilch R, Kurth J, Franken A, Ludescher M, Naskou J, Hallenberger A, Gall CV, Mohr CJ, Lukowski R, Raba K, Jaschinski S, Esposito I, Fischer JC, Fehm T, Niederacher D, Neubauer H, Heinzel T. From in vitro to ex vivo: subcellular localization and uptake of graphene quantum dots into solid tumors. Nanotechnology 2019; 30:395101. [PMID: 31239418 DOI: 10.1088/1361-6528/ab2cb4] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Among various nanoparticles tested for pharmacological applications over the recent years, graphene quantum dots (GQDs) seem to be promising candidates for the construction of drug delivery systems due to their superior biophysical and biochemical properties. The subcellular fate of incorporated nanomaterial is decisive for transporting pharmaceuticals into target cells. Therefore a detailed characterization of the uptake of GQDs into different breast cancer models was performed. The demonstrated accumulation inside the endolysosomal system might be the reason for the particles' low toxicity, but has to be overcome for cytosolic or nuclear drug delivery. Furthermore, the penetration of GQDs into precision-cut mammary tumor slices was studied. These constitute a far closer to reality model system than monoclonal cell lines. The constant uptake into the depth of the tissue slices underlines the systems' potential for drug delivery into solid tumors.
Collapse
Affiliation(s)
- David Kersting
- Condensed Matter Physics Laboratory, Heinrich-Heine-University, D-40204 Düsseldorf, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Fehm T, Meier-Stiegen F, Jaeger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Driemel C, Ruckhaeberle E, Niederacher D, Fischer J, Stoecklein N. Abstract P3-01-12: Clinical safety of diagnostic leukapheresis as a liquid biopsy to collect circulating tumor cells in primary and metastatic breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The enumeration of circulating tumor cells (CTCs) has been shown to be of prognostic relevance for neoadjuvant, adjuvant and metastatic setting of breast cancer in multiple clinical trials. Moreover, the serial determination of CTCs enables therapy monitoring in the metastatic setting. One major caveat is the low number of CTCs detected by established methods which limits the possibility for further evaluation including phenotyping and genotyping. Therefore, the clinical use of CTCs as liquid biopsy for making therapy decisions is still under discussion. Diagnostic leukapheresis (DLA) has been previously established by our research group and implemented in the workflow for isolation and detection of CTCs enabling a reliable detection of CTCs at high frequency. The aim of this clinical study was to assess the safety of leukapheresis in 39 patients with primary and metastatic breast cancer.
Methods: DLA was performed at least 1d before surgery or chemotherapy. A median blood volume of 2.7 L (range, 1.0 L–5.3 L) was processed. Citrate dextrose solution A was used for anticoagulation with ratios ranging from 11:1 to 24:1. Complete blood count as well as measuring blood pressure and heart rate was performed before start of DLA and immediately after DLA. CTCs were enumerated using the CellSearch system. DLA products containing a median number of 1,8x108 MNCs were processed.
Results: 41 patients were eligible for DLA. Only in two patients DLA could not be performed due to technical problems. Thirty-nine patients underwent leukapheresis. Twenty-six patients had non metastatic breast cancer. Thirteen patients were diagnosed with metastatic breast cancer. Severe adverse events including hypotension, nauseas, tingling e.g. resulting in interruption of apheresis were not observed. The DLA did not interfere with the start of chemotherapy or surgery. Complete blood count before and after DLA showed statistic significant but clinically irrelevant decrease in numbers of leukocytes, thrombocytes, hemoglobin and the percentage of hematocrit. In 11/21 DLA samples (52%) of patients with primary breast cancer CTCs were detected. Number of CTCs ranged from 1 to 51. In 11/13 DLA samples (85%) of patients with MBC CTCs were detected. Number of CTCs ranged from 1 to 2913.
Conclusion: Establishing a routine DLA protocol we demonstrated that this procedure is clinically safe and can be implemented into the clinical workflow of breast cancer patient care.
Citation Format: Fehm T, Meier-Stiegen F, Jaeger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Driemel C, Ruckhaeberle E, Niederacher D, Fischer J, Stoecklein N. Clinical safety of diagnostic leukapheresis as a liquid biopsy to collect circulating tumor cells in primary and metastatic breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-12.
Collapse
Affiliation(s)
- T Fehm
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - F Meier-Stiegen
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - B Jaeger
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - F Reinhardt
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - J Naskou
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - A Franken
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - H Neubauer
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - C Driemel
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - E Ruckhaeberle
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - D Niederacher
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - J Fischer
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| | - N Stoecklein
- University Hospital Duesseldorf, Duesseldorf, Germany; Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Duesseldorf, Germany
| |
Collapse
|
4
|
Fehm TN, Meier‐Stiegen F, Driemel C, Jäger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Neves RP, Dalum G, Ruckhäberle E, Niederacher D, Rox JM, Fischer JC, Stoecklein NH. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A 2018; 93:1213-1219. [DOI: 10.1002/cyto.a.23669] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 10/11/2018] [Accepted: 10/17/2018] [Indexed: 01/21/2023]
Affiliation(s)
- Tanja N. Fehm
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Franziska Meier‐Stiegen
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Christiane Driemel
- Faculty of the Heinrich‐Heine, General, Visceral and Pediatric SurgeryUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Bernadette Jäger
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Florian Reinhardt
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Johanna Naskou
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - André Franken
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Hans Neubauer
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Rui P.L. Neves
- Faculty of the Heinrich‐Heine, General, Visceral and Pediatric SurgeryUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Guus Dalum
- Faculty of the Heinrich‐Heine, General, Visceral and Pediatric SurgeryUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Eugen Ruckhäberle
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Dieter Niederacher
- Department of Obstetrics and Gynecology, Faculty of the Heinrich‐HeineUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Jutta M. Rox
- Faculty of the Heinrich‐Heine, Institute for Transplantation Diagnostics and Cell TherapeuticsUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Johannes C. Fischer
- Faculty of the Heinrich‐Heine, Institute for Transplantation Diagnostics and Cell TherapeuticsUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| | - Nikolas H. Stoecklein
- Faculty of the Heinrich‐Heine, General, Visceral and Pediatric SurgeryUniversity Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia Germany
| |
Collapse
|
5
|
Naskou J, Rudelius M, Beiter Y, Fehm T, Niederacher D, Templin MF, Neubauer H. Increased EZH2 protein expression correlates with a better disease-free survival in ovarian cancer patients. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Naskou
- Heinrich-Heine University Düsseldorf, Department of Gynaecology and Obstetrics, Düsseldorf, Deutschland
| | - M Rudelius
- Heinrich-Heine University Düsseldorf, Department of Pathology, Düsseldorf, Deutschland
| | - Y Beiter
- University of Tuebingen, NMI Natural and Medical Sciences Institute, Reutlingen, Deutschland
| | - T Fehm
- Heinrich-Heine University Düsseldorf, Department of Gynaecology and Obstetrics, Düsseldorf, Deutschland
| | - D Niederacher
- Heinrich-Heine University Düsseldorf, Department of Gynaecology and Obstetrics, Düsseldorf, Deutschland
| | - MF Templin
- University of Tuebingen, NMI Natural and Medical Sciences Institute, Reutlingen, Deutschland
| | - H Neubauer
- Heinrich-Heine University Düsseldorf, Department of Gynaecology and Obstetrics, Düsseldorf, Deutschland
| |
Collapse
|
6
|
van Rensburg R, Naskou J, Hagenbeck C, Neubauer H, Niederacher D, Fehm T, Beyer I. Characterization of third-trimester amniotic fluid stem cells. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Naskou J, Beiter Y, Fehm T, Niederacher D, Neubauer H, Templin MF. Differenziell aktivierte Signaltransduktionswege im platinresistenten Ovarialkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Naskou J, Heubach Y, Treindl F, Fehm T, Niederacher D, Neubauer H, Templin M. Detection of cellular signal transduction pathways in platinum-resistant ovarian cancer. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1560008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Baumbach H, Naskou J, Yang Y, Niederacher D, Maxwell C, Fehm T, Fleisch M, Honisch E, Mei Q. BRCA1-abhängige Expression des „Receptor for Hyaluron Mediated Motility“ (RHAMM) in Mammakarzinomen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|